StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)

Close on Nov 18, 2026Market cap $4.74BP/E –Yield –

Travere Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Travere Therapeutics's pe ratio was 15.8× on Oct 31, 2016, against 248.4× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2016Oct 31, 201615.8×+0.7
2015Dec 31, 201515.2×–

More Travere Therapeutics figures

See a number that looks wrong?